Skip to main content

Table 1 Baseline characteristics of 586 patients with Parkinson’s disease

From: Sex and onset-age-related features of excessive daytime sleepiness and night-time sleep in patients with Parkinson’s disease

Characteristica Male
(n = 347)
Female
(n = 239)
P-value EOPD (n = 86) LOPD (n = 500) P-value
Age, years 65.7 ± 10.2 64.1 ± 9.03 0.049 49.5 ± 6.8 67.7 ± 7.5 <  0.001
Age at onset of PD, years 61.5 ± 10.2 60. 6 ± 9.0 0.294 45.1 ± 5.2 63.9 ± 7.4 <  0.001
Education, years 9.0 (6.0–12.0) 9.0 (2.0–9.0) <  0.001 9.0 (6.0–12.0) 9.0 (6.0–12.0) 0.030
Duration of disease, months 36.0 (22.0–72.0) 36.0 (16.0–60.0) 0.047 41.0 (17.8–84.0) 36.0 (18.0–63.8) 0.433
Daily LED, mg/d 300 (0.0–400.0) 200 (0.0–400.0) 0.480 225 (0.0–450.0) 250 (0.0–400.0) 0.773
Hoehn-Yahr stage 2.0 (1.5–2.5) 2.0 (1.5–2.5) 0.109 2.0 (1.5–2.5) 2.0 (1.5–2.5) 0.249
UPDRS I 3.0 (2.0–5.0) 3.0 (2.0–4.0) 0.790 3.0 (1.0–4.0) 3.0 (2.0–5.0) <  0.001
UPDRS II 9.0 (8.0–14.0) 10.0 (7.0–14.0) 0.240 9.0 (5.0–12.0) 11.0 (7.0–14.0) 0.001
UPDRS III 24.0 (16.0–33.0) 22.0 (12.0–30.0) 0.004 21.0 (14.5–32.0) 24.0 (15.0–32.8) 0.430
Motor subtype    0.104    0.023
 TD 62 (17.8) 52 (21.7)   22 (25.6) 88 (17.6)  
 A-R 252 (72.8) 161 (67.3)   50 (58.1) 363 (72.6)  
 MX 33 (9.4) 26 (11)   14 (16.3) 49 (9.8)  
Motor fluctuation 47 (13.5) 39 (16.3) 0.330 11 (12.8) 75 (15.0) 0.583
Dyskinesia 14 (4.0) 15 (6.3) 0.219 4 (4.7) 25 (5.0) 0.890
Cigarette smoking 120 (34.6) 5 (2.1) <  0.001 23 (26.7) 102 (20.4) 0.185
Family history of PD 25 (7.2) 17 (7.1) 0.966 11 (12.8) 31 (6.2) 0.029
History of hypertension 82 (23.6) 52 (21.8) 0.596 12 (14.0) 122 (24.4) 0.033
History of diabetes mellitus 24 (6.9) 14 (5.9) 0.609 3 (3.5) 35 (7.0) 0.222
Use of levodopa 209 (60.2) 146 (61.1) 0.835 45 (52.3) 310 (62.0) 0.090
Use of dopamine agonists 98 (28.2) 57 (23.8) 0.347 22 (25.6) 133 (26.6) 0.843
Use of MAOBI 30 (8.6) 15 (6.3) 0.290 10 (11.6) 35 (7.0) 0.137
Use of amantadine 51 (14.7) 31 (13.0) 0.554 15 (17.4) 67 (13.4) 0.318
Use of COMTI 12 (3.5) 3 (1.3) 0.097 0 (0.0) 15 (3.0) 0.104
RBD 126 (36.2) 72 (30.0) 0.110 24 (27.9) 173 (34.2) 0.253
HRSD 7.0 (3.0–13.0) 7.0 (3.0–15.0) 0.446 7.0 (2.0–13.0) 7.0 (3.0–14.0) 0.682
MMSE 28.0 (26.0–29.0) 27.0 (26.0–29.0) 0.055 29.0 (27.0–30.0) 28.0 (26.0–29.0) < 0.001
  1. aContinuous variables are expressed as mean ± standard deviation or as median (interquartile range). Categorical variables are expressed as frequency (percent)
  2. Abbreviations: PD Parkinson’s disease, LED Levodopa-equivalent dose, UPDRS I Score of first part of Unified Parkinson Disease Rating Scale, UPDRS II Score of second part of Unified Parkinson Disease Rating Scale, UPDRS III Score of third part of Unified Parkinson Disease Rating Scale, TD Tremor Dominant, A-R Akinetic-rigid, MX Mixed, MAOBI Monoamine oxidase-B inhibitor, COMTI Catechol-O-methyltransferase inhibitor, RBD Rapid eye movement sleep behavior disorder, HRSD Hamilton Rating Scale for Depression, MMSE Mini-mental State Examination